Information  X 
Enter a valid email address

Ergomed plc (ERGO)


Monday 28 February, 2022

Ergomed plc

Ergomed Notice of Preliminary Results

RNS Number : 9439C
Ergomed plc
28 February 2022




Notice of Preliminary Results



Guildford, UK - 28 February 2022: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, will announce its preliminary results for the year ending 31 December 2021 on Tuesday 29 March 2022.


Miroslav Reljanović, Executive Chairman, Richard Barfield, Chief Financial Officer, and Keith Byrne, Senior Vice-President, Capital Markets & Strategy, will host an in-person briefing for analysts at 9.30am GMT on the day of the results at the offices of Numis, 45 Gresham St, London EC2V 7BF. There will also be a live webcast and conference call with a Q&A session.







Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)

Richard Barfield (Chief Financial Officer)

Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

Numis (Nominated Advisor and Joint Broker)

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Euan Brown (Nominated Adviser)

James Black (Broker)


Peel Hunt LLP (Joint Broker)

James Steel / Dr Christopher Golden 


  Tel: +44 (0) 20 7418 8900



Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal

[email protected]

Angela Gray



About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: .


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t